Community-Acquired Pneumonia — Diagnosis and Evidence-Based Treatment
Community-acquired pneumonia remains a leading cause of infectious disease mortality worldwide. Risk-stratify all patients using CURB-65 or PSI/PORT scoring, together with clinical judgment, to decide between outpatient and inpatient care; these scores were not designed to select the level of care for a hospitalized patient, so the choice between the general ward and the intensive care unit follows the ATS/IDSA severity criteria and clinical judgment. For outpatient management, initiate amoxicillin 1 g PO TID or doxycycline 100 mg PO BID as monotherapy in healthy adults without comorbidities, and add a macrolide for those with risk factors. Hospitalized patients with non-severe CAP require combination therapy with ceftriaxone 1–2 g IV daily plus azithromycin 500 mg IV/PO daily, or monotherapy with a respiratory fluoroquinolone. Assess clinical response at 48–72 hours, transition to oral therapy once hemodynamically stable, and target a total antibiotic duration of 5–7 days guided by clinical improvement and procalcitonin trends.
Pathophysiology
Community-acquired pneumonia develops when pathogenic microorganisms overwhelm the host pulmonary defense mechanisms and establish infection within the lower respiratory tract. The primary route of inoculation is microaspiration of oropharyngeal secretions colonized with potential pathogens, though direct inhalation of aerosolized droplets predominates for atypical organisms such as Legionella pneumophila and respiratory viruses. Once organisms reach the terminal bronchioles and alveoli, the innate immune response mounts a vigorous neutrophilic inflammatory cascade that, while essential for pathogen clearance, simultaneously causes collateral alveolar damage, exudative fluid accumulation, and impaired gas exchange.
- Core Mechanism
- Microbial invasion of the alveolar epithelium triggers alveolar macrophage activation, toll-like receptor signaling (TLR-2, TLR-4), and massive neutrophil recruitment via IL-8 and CXCL-1, leading to exudative consolidation and ventilation-perfusion mismatch
- Key Pathway
- NF-kB-mediated cytokine release (TNF-alpha, IL-1-beta, IL-6) drives systemic inflammatory response; complement activation (C3a, C5a) enhances opsonization and leukocyte chemotaxis into the alveolar space
- Genetic Factors
- Polymorphisms in mannose-binding lectin (MBL2), surfactant proteins SP-A and SP-D, TLR-4 (Asp299Gly), and FCGR2A influence susceptibility to pneumococcal disease and severity of illness
- Risk Factors
- MODIFIABLE: tobacco smoking (3-fold risk), alcohol misuse, poor oral hygiene, immunosuppressive medications | NON-MODIFIABLE: age over 65, chronic lung disease (COPD, asthma, bronchiectasis), diabetes mellitus, congestive heart failure, prior splenectomy
- Biomarkers
- Procalcitonin (PCT) greater than 0.25 ng/mL suggests bacterial etiology; C-reactive protein (CRP) greater than 100 mg/L correlates with severe disease; lactate greater than 2 mmol/L indicates tissue hypoperfusion and sepsis risk
The pathophysiologic sequence begins when aspirated or inhaled organisms adhere to the alveolar epithelium through specific adhesins such as pneumococcal phosphorylcholine and choline-binding proteins. This triggers resident alveolar macrophages to recognize pathogen-associated molecular patterns (PAMPs) via pattern recognition receptors, initiating a cytokine cascade that recruits neutrophils from the pulmonary capillary bed. Neutrophil degranulation releases elastase, reactive oxygen species, and matrix metalloproteinases that destroy invading organisms but simultaneously damage the alveolocapillary membrane. The resulting increase in capillary permeability allows protein-rich edema fluid, fibrin, red blood cells, and inflammatory cells to flood the alveolar spaces, producing the characteristic radiographic consolidation. Surfactant dysfunction occurs as type II pneumocyte injury reduces production and inflammatory exudate inactivates existing surfactant, promoting atelectasis and further worsening ventilation-perfusion mismatch. In severe cases, bilateral alveolar damage can progress to acute respiratory distress syndrome. Streptococcus pneumoniae remains the most frequently identified pathogen, followed by Haemophilus influenzae and Moraxella catarrhalis among typical bacteria. Atypical pathogens including Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila lack a classical cell wall, render Gram stain unhelpful, and require intracellular-active antibiotics for eradication. Respiratory viruses including influenza, SARS-CoV-2, and respiratory syncytial virus may cause primary viral pneumonia or predispose to secondary bacterial superinfection.
Diagnostic Protocol
Suspect community-acquired pneumonia in any patient presenting with acute-onset cough (productive or dry), fever or hypothermia, dyspnea, and pleuritic chest pain, particularly when accompanied by focal auscultatory findings such as crackles, bronchial breath sounds, or egophony. Physical examination findings alone are insufficient for diagnosis; a chest radiograph demonstrating a new pulmonary infiltrate is required to confirm the diagnosis and distinguish pneumonia from acute bronchitis, heart failure exacerbation, or pulmonary embolism. Once the diagnosis is confirmed, the immediate clinical priority is severity assessment using a validated scoring system to determine site of care, because this single decision has the greatest impact on both cost and patient outcomes.
Severity Scoring: CURB-65
| Score | Criteria Met | 30-Day Mortality | Recommended Site of Care |
|---|---|---|---|
| 0 | No CURB-65 criteria present | 0.6% | Outpatient treatment |
| 1 | One criterion (most commonly age ≥65) | 2.7% | Outpatient; consider brief observation |
| 2 | Two criteria present | 6.8% | Hospital admission (short-stay or general ward) |
| 3 | Three criteria present | 14.0% | Hospital admission; assess for ICU |
| 4–5 | Four or five criteria present | 27.8% | Hospital admission; assess for ICU using the ATS/IDSA severity criteria (Step 3) |
CURB-65 components: Confusion (new-onset, AMT score ≤8), Urea >7 mmol/L (>20 mg/dL), Respiratory rate ≥30/min, Blood pressure (SBP <90 or DBP ≤60 mmHg), Age ≥65. Each criterion scores one point (total range 0–5). The PSI/PORT score is an alternative 20-variable model that incorporates demographics, comorbidities, vital signs, and laboratory values to stratify patients into five risk classes (I through V). Risk Class I–II patients (mortality <1%) are safely managed as outpatients, Class III (mortality 0.9–2.8%) may be considered for brief observation, and Class IV–V (mortality 8–29%) require inpatient management. CURB-65 is preferred in emergency settings for its simplicity, while PSI/PORT performs better for identifying truly low-risk patients safe for discharge.
Diagnostic Workup
| Test | Rationale / What It Shows | Sensitivity | Specificity |
|---|---|---|---|
| Chest radiograph (PA + lateral) | Confirms pneumonia (new infiltrate/consolidation); identifies complications (effusion, cavitation, multi-lobar disease) | 75–85% | 85–95% |
| Sputum Gram stain + culture | Identifies causative organism and guides targeted therapy; obtain before antibiotics when possible | 50–60% | 85–90% |
| Legionella urinary antigen | Detects L. pneumophila serogroup 1 (accounts for 80% of Legionella CAP); rapid turnaround (<1 hour) | 70–80% | 99% |
| Pneumococcal urinary antigen | Detects S. pneumoniae C-polysaccharide; remains positive despite prior antibiotics; useful when sputum unavailable | 65–80% | 90–97% |
| Blood cultures (2 sets) | Identify bacteremia (positive in 5–14% of hospitalized CAP); essential for severe CAP and ICU patients | 5–14% | >99% |
| Procalcitonin (PCT) | PCT >0.25 ng/mL supports bacterial etiology; serial levels guide antibiotic duration (stop when <0.25 or ≥80% decline from peak) | 78% | 83% |
Differential Diagnosis
| Condition | Distinguishing Feature | Key Workup |
|---|---|---|
| Acute decompensated heart failure | Bilateral perihilar vascular congestion (butterfly pattern), elevated JVP, peripheral edema, B-lines on lung ultrasound; BNP >400 pg/mL | BNP/NT-proBNP, echocardiogram, CXR showing cardiomegaly + cephalization |
| Pulmonary embolism | Sudden-onset pleuritic chest pain and dyspnea without productive cough; risk factors for DVT; hypoxemia disproportionate to CXR findings; Hampton hump or Westermark sign | D-dimer, CT pulmonary angiography, Wells score |
| Lung abscess | Subacute presentation with foul-smelling sputum, history of aspiration risk (alcoholism, seizures, dysphagia); CXR shows thick-walled cavitary lesion with air-fluid level | CT chest with contrast, sputum for anaerobic culture, bronchoscopy if non-resolving |
| Acute exacerbation of COPD | Increased baseline dyspnea and sputum volume/purulence without new infiltrate on imaging; diffuse wheezing rather than focal crackles; no fever or low-grade only | CXR (no consolidation), spirometry if stable, sputum culture for purulent exacerbation |
| Tuberculosis | Chronic cough >3 weeks, night sweats, weight loss; upper lobe cavitary lesion; epidemiologic risk (endemic area, immunosuppression, incarceration) | AFB smear and culture (3 sputum specimens), IGRA or PPD, CXR upper lobe infiltrate |
Treatment Algorithm
The overarching goal of CAP treatment is rapid eradication of the causative pathogen, prevention of complications such as empyema and bacteremia, and early transition from parenteral to oral therapy. Empiric antibiotic selection is stratified by site of care and patient comorbidities, with regimens designed to cover both typical and atypical organisms. Administer the first antibiotic dose within 4 hours of presentation (ideally within 1 hour for severe CAP), as delays beyond this window are associated with increased mortality. De-escalation from broad-spectrum to targeted therapy should occur as soon as microbiologic data allow, typically by 48–72 hours. Total treatment duration for uncomplicated CAP is 5–7 days, guided by clinical response and procalcitonin kinetics. Grade A
Healthy outpatients without chronic heart, lung, liver, or renal disease and no antibiotic use in the prior 90 days can be managed with monotherapy targeting the most common typical pathogen (S. pneumoniae). Expected clinical improvement within 48–72 hours. Grade A
Amoxicillin: Amoxicillin 1 g PO TID × 5–7 days
Alternative (penicillin allergy or atypical coverage): Doxycycline 100 mg PO BID × 5–7 days
Outpatient with comorbidities (COPD, diabetes, heart failure, alcoholism, or antibiotic use in prior 90 days): add macrolide for atypical coverage or use respiratory fluoroquinolone monotherapy. Grade B
Combination: Amoxicillin-clavulanate 875/125 mg PO BID × 5–7 days plus Azithromycin 500 mg PO day 1, then 250 mg PO daily × 4 days
Hospitalized patients with non-severe CAP require IV antibiotics with dual coverage of typical and atypical organisms. The preferred regimen combines a beta-lactam with a macrolide. Respiratory fluoroquinolone monotherapy is an acceptable alternative when beta-lactam allergy or macrolide intolerance precludes combination therapy. Target transition from IV to oral antibiotics within 48–72 hours once clinical stability criteria are met. Grade A
Preferred: Ceftriaxone 1–2 g IV daily plus Azithromycin 500 mg IV/PO daily
Alternative beta-lactam: Ampicillin-sulbactam 3 g IV q6h plus azithromycin
Fluoroquinolone monotherapy: Levofloxacin 750 mg PO/IV daily × 5 days or Moxifloxacin 400 mg PO daily × 5 days
MRSA or Pseudomonas risk in non-severe CAP: after prior respiratory isolation of MRSA or P. aeruginosa, add coverage for that pathogen and obtain cultures (and a nasal PCR for MRSA) to allow de-escalation. After recent hospitalization and receipt of parenteral antibiotics in the last 90 days, obtain cultures but withhold MRSA or Pseudomonas coverage unless culture results are positive; if a rapid MRSA nasal PCR is available, withhold MRSA coverage when it is negative and add coverage when it is positive.
ICU-level care is indicated when major criteria are met: invasive mechanical ventilation or vasopressor requirement. Minor criteria include respiratory rate ≥30, PaO2/FiO2 ratio ≤250, multi-lobar infiltrates, confusion, BUN >20 mg/dL, leukopenia (WBC <4,000), thrombocytopenia (platelets <100,000), hypothermia (<36 C), and hypotension requiring aggressive fluid resuscitation. Three or more minor criteria also warrant ICU admission. Cover MRSA or Pseudomonas empirically only when a risk factor for that pathogen is present: prior respiratory isolation of MRSA or P. aeruginosa, or recent hospitalization and receipt of parenteral antibiotics in the last 90 days (the guideline calls for validating these risk factors with local data). In severe CAP with such a risk factor, add coverage for that pathogen and obtain cultures (and a nasal PCR for MRSA) to allow de-escalation if cultures are negative and the patient is improving. For non-severe inpatients, follow Step 2: after prior respiratory isolation of that pathogen, add coverage and obtain cultures; after recent hospitalization and receipt of parenteral antibiotics, obtain cultures and withhold coverage unless culture results are positive (for MRSA, withhold coverage if a rapid nasal PCR is negative and add it if the PCR is positive). Grade A
Standard ICU: Ceftriaxone 2 g IV daily plus Azithromycin 500 mg IV daily
If MRSA risk: add Vancomycin AUC-guided dosing (target AUC 400–600 mg·h/L) or Linezolid 600 mg IV/PO q12h
If Pseudomonas risk: substitute Piperacillin-tazobactam 4.5 g IV q8h (extended infusion over 4h) or Cefepime 2 g IV q8h for ceftriaxone, plus azithromycin
Special Populations
| Population | Drug / Consideration | Specific Recommendation |
|---|---|---|
| Renal Impairment | Levofloxacin | CrCl 20–49 mL/min: 750 mg IV/PO q48h. CrCl <20 mL/min or hemodialysis: 500 mg IV/PO q48h. No dose adjustment needed for ceftriaxone or azithromycin. |
| Hepatic Impairment | Moxifloxacin, azithromycin | Avoid moxifloxacin in Child-Pugh C (hepatotoxicity risk, no dose adjustment available). Use azithromycin with caution in Child-Pugh B–C; monitor LFTs weekly. Ceftriaxone: reduce dose if combined hepatic + renal impairment. |
| Elderly (≥65) | Fluoroquinolones | Increased risk of tendon rupture (6-fold in patients >60), C. difficile infection, and QTc prolongation. Prefer beta-lactam plus macrolide over fluoroquinolone when possible. Assess renal function with Cockcroft-Gault; adjust levofloxacin accordingly. |
| Pregnancy | Beta-lactams preferred | Amoxicillin and ceftriaxone are considered safe across all trimesters. AVOID fluoroquinolones (cartilage toxicity risk) and doxycycline (dental/bone effects after 16 weeks). Azithromycin is acceptable for atypical coverage. |
| Pediatric | Amoxicillin, ceftriaxone | Amoxicillin 90 mg/kg/day PO divided TID (max 3 g/day) for outpatient. Ceftriaxone 50–100 mg/kg IV daily (max 2 g) for inpatient. Add azithromycin 10 mg/kg day 1 (max 500 mg), then 5 mg/kg daily × 4 days for atypical coverage in children ≥5 years. |
| Aspiration Risk | Ampicillin-sulbactam | Add anaerobic coverage with ampicillin-sulbactam 3 g IV q6h or amoxicillin-clavulanate for outpatients. Consider metronidazole 500 mg IV/PO q8h as add-on if lung abscess suspected. Avoid clindamycin as first-line due to rising anaerobic resistance. |
Drug Interactions
| Drug | Interacting Agent | Mechanism | Clinical Effect | Management |
|---|---|---|---|---|
| Azithromycin | Amiodarone, sotalol, ondansetron | Additive QTc prolongation via delayed cardiac repolarization (IKr channel blockade) | Risk of torsades de pointes, sudden cardiac death | Check baseline ECG and QTc. If QTc >500 ms, substitute doxycycline for azithromycin. Monitor telemetry in hospitalized patients on concurrent QTc-prolonging drugs. |
| Levofloxacin | Oral divalent/trivalent cations (Al, Mg, Ca, Fe, Zn) | Chelation of fluoroquinolone by metal cations in GI tract, reducing oral bioavailability by 50–90% | Subtherapeutic antibiotic levels, treatment failure | Administer levofloxacin 2 hours before or 6 hours after antacids, sucralfate, iron supplements, or multivitamins containing metals. |
| Levofloxacin | Warfarin | CYP1A2 inhibition reduces warfarin S-isomer metabolism; displacement from albumin binding | INR elevation (1.5–3-fold increase), bleeding risk | Check INR within 3–5 days of starting fluoroquinolone. Reduce warfarin dose by 25–33% empirically. Consider using ceftriaxone plus azithromycin instead to avoid interaction. |
| Ceftriaxone | Calcium-containing IV solutions (Ringer’s lactate) | Ceftriaxone-calcium precipitation forms insoluble particulates in tubing and potentially in vivo | Fatal pulmonary/renal microemboli in neonates; risk theoretical in adults | Never co-infuse ceftriaxone with calcium-containing solutions through the same line. In neonates, contraindicated within 48 hours of calcium administration. In adults, flush line between infusions. |
Community-acquired pneumonia is a lung infection that causes cough, fever, and difficulty breathing. Your doctor will determine how sick you are using a scoring system and decide whether you can be treated at home with oral antibiotics or need to be admitted to the hospital for intravenous medications. Most people start feeling better within 2–3 days. The full course of antibiotics is typically 5–7 days. It is important to complete the entire prescribed course even if you feel better, and to return for follow-up if symptoms worsen or do not improve after 3 days.
Treatment by site of care
Adult CAP: empiric antibiotic regimens
Non-pregnant, normal renal function.
Outpatient, no comorbidities
Management
- Amoxicillin 1 g PO TID; or doxycycline 100 mg PO BID for penicillin allergy or atypical coverage
- Macrolide alone only if local pneumococcal macrolide resistance <25%
Outpatient with comorbidities
Management
- Amoxicillin-clavulanate 875/125 mg PO BID plus azithromycin 500 mg day 1, then 250 mg daily × 4 days
- Or respiratory fluoroquinolone monotherapy
Inpatient, non-severe CAP
Management
- Ceftriaxone 1–2 g IV daily plus azithromycin 500 mg IV/PO daily
- Beta-lactam allergy or macrolide intolerance: levofloxacin 750 mg PO/IV daily or moxifloxacin 400 mg PO daily, alone
- Only risk recent hospitalization plus parenteral antibiotics: cover MRSA or Pseudomonas only if cultures or MRSA nasal PCR are positive
Severe CAP: 1 major or ≥3 minor ATS/IDSA criteria
Management
- Ceftriaxone 2 g IV daily plus azithromycin 500 mg IV daily
- MRSA risk: add vancomycin (AUC-guided, target 400–600 mg·h/L) or linezolid 600 mg IV/PO q12h
- Pseudomonas risk: piperacillin-tazobactam or cefepime in place of ceftriaxone, plus azithromycin
Cover MRSA or Pseudomonas only with a risk factor for that pathogen: prior respiratory isolation, or hospitalization plus parenteral antibiotics in the last 90 days.
No improvement by 72 hours: reassess the diagnosis; look for empyema, lung abscess or a resistant organism.
Monitoring & Surveillance
Monitoring in CAP serves two concurrent goals: assessing response to empiric therapy and detecting complications that require intervention. The critical inflection point occurs at 48–72 hours after initiating antibiotics, when the majority of patients with appropriate coverage should demonstrate initial clinical improvement including defervescence, declining heart rate, and stabilizing respiratory parameters. Failure to improve at this juncture demands reassessment of the diagnosis, antibiotic coverage adequacy, and evaluation for complications such as parapneumonic effusion, empyema, or lung abscess. Serial procalcitonin measurements offer an objective biomarker-guided approach to antibiotic duration, allowing safe early discontinuation when levels fall below 0.25 ng/mL or decrease by 80% or more from the peak value. For hospitalized patients, daily assessment of clinical stability criteria guides the decision to transition from intravenous to oral therapy and determines readiness for hospital discharge.
- CBC with differential (WBC, neutrophil count)
- BMP: BUN, creatinine, electrolytes, glucose
- Procalcitonin level (baseline for trending)
- CRP (optional; correlates with severity)
- Arterial blood gas or SpO2 on room air
- Blood cultures (2 sets) before antibiotics
- Clinical stability assessment (T, HR, RR, BP, SpO2)
- Repeat procalcitonin (assess for ≥80% decline)
- Review microbiologic data; de-escalate therapy
- Assess IV-to-oral transition eligibility
- Procalcitonin if using to guide discontinuation (<0.25 ng/mL target)
- Confirm afebrile ≥48 hours and ≤1 sign of instability
- Assess for discharge readiness (oral tolerance, stable vitals, adequate home support)
- Follow-up chest radiograph (especially age >50 or smokers) to confirm radiographic resolution
- Evaluate for underlying malignancy if non-resolving infiltrate
- Assess smoking cessation, pneumococcal/influenza vaccination status
Response & Safety Parameters
| Parameter | Target / Threshold | Frequency | Action if Abnormal |
|---|---|---|---|
| Temperature | <37.8 °C for ≥24 consecutive hours | Every 4–8 hours | Persistent fever at 72 hours: obtain CT chest, reassess coverage, check for empyema or abscess |
| Procalcitonin | <0.25 ng/mL or ≥80% decline from peak | Baseline, 48–72h, day of planned discontinuation | If PCT remains elevated or rising: extend therapy, repeat cultures, consider resistant organism or non-infectious diagnosis |
| Oxygen saturation | SpO2 >90% on room air (or >88% if COPD) | Continuous or every 4 hours | Worsening hypoxemia despite 48h therapy: escalate to high-flow nasal cannula or NIV; ICU transfer if PaO2/FiO2 <200 |
| WBC count | Trending toward normalization (4,500–11,000/microL) | Baseline and every 48–72 hours | Persistent leukocytosis (>15,000) or new leukopenia (<4,000) at 72 hours: broaden coverage, obtain CT, consider bone marrow suppression or overwhelming sepsis |
| Renal function (Cr, BUN) | Stable or improving from baseline | Every 24–48 hours if on vancomycin; otherwise baseline and PRN | Rising creatinine: assess volume status, hold nephrotoxins, adjust vancomycin per AUC-guided protocol. Vancomycin AUC target 400–600 mg·h/L. |
Clinical Commentary
Pulmonology consultation: Non-resolving pneumonia (persistent infiltrate at 6–8 weeks despite appropriate therapy) requires bronchoscopy with BAL to evaluate for endobronchial obstruction (malignancy), unusual organisms (fungal, mycobacterial), or organizing pneumonia.
Thoracic surgery / interventional radiology: Parapneumonic effusion with pH <7.20 or positive fluid culture (empyema) requires chest tube drainage or video-assisted thoracoscopic surgery (VATS) decortication. Lung abscess >6 cm failing 4–6 weeks of IV antibiotics may need CT-guided percutaneous drainage.
Infectious disease consultation: Isolation of MRSA, Pseudomonas, or other multidrug-resistant organisms; failure of two empiric regimens; or immunocompromised host with atypical pathogens (Pneumocystis, CMV, invasive aspergillosis).
- Optimal role of corticosteroids as adjunctive therapy in severe CAP remains debated; some trials show reduced time to clinical stability, but benefit in non-ICU patients is unclear
- Whether macrolide immunomodulatory effects (anti-inflammatory beyond antimicrobial) contribute independently to improved outcomes in CAP is not definitively established
- The threshold for adding anti-MRSA and anti-Pseudomonal coverage lacks validated prediction tools; current guidance relies on risk factor assessment rather than prospective scoring systems
Practice Insights: Lessons From the Bedside
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Across emergency medicine, inpatient medicine, and infectious disease services, community-acquired pneumonia is the field where the 2019 ATS/IDSA guideline retirement of the HCAP category plus the 2023 CAPE-COD trial (Dequin et al., NEJM 2023) supporting hydrocortisone in severe CAP plus shorter antibiotic duration evidence has substantially reshaped management. The clearest outcome gains fall to severe CAP patients in the ICU receiving hydrocortisone per CAPE-COD evidence and to outpatient CAP patients no longer receiving macrolide monotherapy in regions with high pneumococcal macrolide resistance.
What the Guideline Misses
The 2023 CAPE-COD trial (Dequin et al., NEJM 2023) demonstrated that hydrocortisone 200 mg/day by continuous IV infusion for 4 or 7 days, as determined by clinical improvement, followed by tapering for a total of 8 or 14 days, reduced 28-day mortality in adults admitted to the ICU for severe CAP (6.2% vs 11.9% with placebo; absolute difference, 5.6 percentage points). The 2019 ATS/IDSA guidelines predate this evidence; they recommend not routinely using corticosteroids in adults with nonsevere CAP and suggest not routinely using them in adults with severe CAP, but the field has shifted toward selective hydrocortisone in severe ICU CAP. CAPE-COD required at least one severity criterion: a Pneumonia Severity Index above 130, mechanical ventilation (invasive or noninvasive) with PEEP of 5 cm H2O or more, high-flow oxygen with FiO2 of 50% or more and a PaO2/FiO2 ratio below 300, or a partial rebreathing mask with a reservoir bag and a PaO2 below a flow-dependent threshold. Its exclusions included vasopressor treatment for septic shock at inclusion, a clinical history suggesting aspiration of gastric content, a positive rapid influenza PCR, active tuberculosis or fungal infection, active viral hepatitis or active infection with herpes viruses, and myelosuppression; for severe influenza pneumonia, the 2019 ATS/IDSA guideline suggests not routinely using corticosteroids.
Patterns That Recur
Macrolide monotherapy (azithromycin or clarithromycin) for outpatient CAP in regions where Streptococcus pneumoniae macrolide resistance exceeds 25% is the practice gap that recurs most often. The 2019 ATS/IDSA guidelines recommend amoxicillin or doxycycline as outpatient first-line where local resistance is high, with macrolide reserved for low-resistance regions. Local antibiogram review at the practice level should drive empiric selection, and routine deferral to “azithromycin Z-pack” produces preventable treatment failures.
A Bedside Heuristic
CURB-65 score plus clinical judgment for site-of-care decisions, rather than any single severity tool in isolation. CURB-65 ≤1 generally outpatient (~3% mortality), ≥2 admission consideration (~10% mortality), ≥3 admission (~22% mortality), with the need for ICU care judged by the ATS/IDSA severity criteria rather than by the score, because CURB-65 was not designed to select the level of care for a hospitalized patient. PSI/PORT is more granular but logistically less practical for ED-level decisions. Social factors (homelessness, drug use, ability to obtain oral medications) override the score when they preclude reliable outpatient management.
The Duration Doctrine
Total antibiotic duration of 5 days for uncomplicated CAP per multiple trials supporting non-inferiority of shorter courses, with extension only when complications (bacteremia, empyema, abscess) or non-typical pathogens (Legionella, Pseudomonas, MRSA) warrant. IV-to-PO switch when afebrile + clinically improving + tolerating oral intake + hemodynamically stable — typically by day 3 of hospitalization. The historical 7-10 day “complete the course” duration is unnecessarily long in most uncomplicated CAP.
Illustrative Scenario
A man in his late sixties presented to the emergency department with 3 days of productive cough, fever to 38.9°C, and progressive dyspnea on exertion. Chest X-ray showed right lower lobe consolidation, and laboratory studies revealed WBC 18,400 with left shift, BUN 32 mg/dL, lactate 1.8, and SpO2 91% on room air. CURB-65 score was 2 (BUN over 19 + age over 65). He was admitted to the inpatient medicine ward on ceftriaxone 1 g IV daily plus azithromycin 500 mg IV daily as combination empiric coverage, plus rapid influenza testing which returned positive for influenza A. Oseltamivir 75 mg twice daily was added for 5 days. He demonstrated clinical improvement by hospital day 3 — afebrile for 24 hours, decreased oxygen requirement, tolerating oral intake — and he was transitioned to oral levofloxacin 750 mg daily, with planned total antibiotic duration 5 days from initial dose. He was discharged on hospital day 4 with completion of antibiotics, oseltamivir, and outpatient follow-up at 4 weeks for chest X-ray to document resolution. He had no readmission and recovered fully.
Protocol Adjustments to the Standard Pathway
- Hydrocortisone 200 mg/day by continuous IV infusion for 4 or 7 days (as determined by clinical improvement), followed by tapering for a total of 8 or 14 days, started no longer than 24 hours after the first severity criterion, in ICU patients with severe CAP who meet the CAPE-COD enrollment criteria (criteria listed under What the Guideline Misses above; the trial excluded patients with a positive rapid influenza PCR, patients receiving vasopressors for septic shock at inclusion, patients with a clinical history suggesting aspiration of gastric content, and patients with active tuberculosis or fungal infection, active viral hepatitis or active infection with herpes viruses, or myelosuppression, and the 2019 ATS/IDSA guideline suggests not routinely using corticosteroids in adults with severe influenza pneumonia) per CAPE-COD 2023 trial (Dequin et al., NEJM 2023) demonstrating a 5.6-percentage-point absolute reduction in 28-day mortality (6.2% vs 11.9% with placebo). The 2019 ATS/IDSA guidelines predate this evidence; selective hydrocortisone in patients who meet these criteria is current best practice.
- Outpatient CAP: amoxicillin or doxycycline where local S. pneumoniae macrolide resistance >25%, not macrolide monotherapy. Local antibiogram review at the practice level drives empiric selection; routine “Z-pack” produces preventable treatment failures in high-resistance regions.
- CURB-65 + clinical judgment for site of care: ≤1 outpatient, ≥2 admission; the need for ICU care is judged by the ATS/IDSA severity criteria, not by the CURB-65 score. Social factors (homelessness, drug use, oral medication access) override score when they preclude reliable outpatient management.
- Total 5-day antibiotic duration for uncomplicated CAP per non-inferiority evidence, with extension only for complications or non-typical pathogens. IV-to-PO switch when afebrile + clinically improving + tolerating PO + hemodynamically stable — typically by day 3.
CAPE‑COD criteria
Hydrocortisone in severe CAP
Adults in ICU for severe CAP with at least one of:
- PSI >130, or ventilation (invasive or NIV) with PEEP ≥5 cm H₂O
- High-flow O₂: FiO₂ ≥50% and PaO₂/FiO₂ <300
- Partial rebreathing mask with reservoir bag and PaO₂ below a flow-dependent cutoff
Not studied in CAPE‑COD, e.g.:
- Vasopressors for septic shock at inclusion
- History suggesting aspiration of gastric content
- Positive rapid influenza PCR
Hydrocortisone 200 mg/day IV
- 4 or 7 days, as determined by clinical improvement, then taper: 8 or 14 days in total
- CAPE‑COD 28‑day mortality: 6.2% vs 11.9% with placebo
Severe influenza pneumonia: 2019 ATS/IDSA suggests not routinely using corticosteroids.
Nonsevere CAP: 2019 ATS/IDSA recommends not routinely using corticosteroids.
Frequently Asked Questions
- Pneumocystis Jirovecii Pneumonia: Diagnosis, Treatment, and Prophylaxis
- Clostridioides difficile Infection — Diagnosis and Targeted Treatment
- Whipple Disease: Diagnosis, Antibiotic Treatment, and Long-Term Management
- Syphilis: Diagnosis, Staging, and Treatment Management
- Legionella Pneumonia: ATS/IDSA Diagnosis with Urinary Antigen Testing and Levofloxacin or Azithromycin Therapy
- Clostridioides difficile Infection: Diagnosis, Risk Stratification, and Fidaxomicin-First Treatment
Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.
- ATS/IDSA 2019 Guideline: Community-acquired Pneumonia in Adults (American Journal of Respiratory and Critical Care Medicine · 2019)